Abstracts tagged "Lupus nephritis"

Abstract Number: 0341 • ACR Convergence 2021
Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data
Meghan Tierney and Chris Rowe, PicnicHealth, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is often underrecognized and difficult to identify retrospectively, presenting challenges for clinicians and researchers hoping to explore this condition using real-world…
Abstract Number: 0966 • ACR Convergence 2021
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Garett Dunlap¹, Allison Billi², Feiyang Ma³, Johann Gudjonsson², J. Michelle Kahlenberg⁴ and Deepak Rao⁵, ¹Harvard University, Somerville, MA, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of California Los Angeles, Los Angelas, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…
Abstract Number: 1485 • ACR Convergence 2021
Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis
Tammy Nowling, Jessalyn Rodgers, Bethany Wolf, Brian Troyer and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a chronic, immune complex-mediated glomerulonephritis affecting up to 60% of patients with lupus. Progression of the most aggressive forms of…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: 0342 • ACR Convergence 2021
RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
Ellen Cody¹, Scott Wenderfer², Qing Ma¹, Angela Merritt¹, Prasad Devarajan¹ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a diagnostic and therapeutic challenge, particularly lupus nephritis (LN). We described a composite score, the Renal Activity Index for…
Abstract Number: 0973 • ACR Convergence 2021
Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants
MacIntosh Cornwell¹, Hanane EL Bannoudi², Elliot Luttrell-Williams¹, Khrystyna Myndzar¹, Alexis Engel³, Peter Izmirly⁴, H. Michael Belmont⁵, Robert Clancy⁶, Jeffrey Berger¹, Kelly Ruggles¹ and Jill Buyon⁶, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY
Background/Purpose: The clinical heterogeneity of SLE with its complex pathogenesis remains challenging as we strive to provide optimal management. The contribution of platelets to endovascular…
Abstract Number: 1503 • ACR Convergence 2021
Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging
Craig Smuda¹, Anna Eichinger², Robert Clancy², Jill Buyon³ and Boris Reizis⁴, ¹NYU Grossman School of Medic ine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The Accelerating Medicines Project (AMP) has enabled significant increases in understanding of SLE nephritis pathology, providing a profile of dozens of leukocyte subsets within…
Abstract Number: 0350 • ACR Convergence 2021
EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis
Ashira Blazer¹, Olusola Ayanlowo², Will Liao³, Dzifa Dey⁴, Jasmin Divers⁵, Uyiekpen Ima-Edomwonyin⁶, Hakeem Olaosebikan⁷, Cristina Lanata⁸, Girish Nadkarni⁹, Jill Buyon¹, Peter Izmirly¹⁰ and Timothy Niewold¹¹, ¹NYU School of Medicine, New York, NY, ²College of Medicine University of Lagos, New York, NY, ³New York Genome Center, New York, NY, ⁴University of Ghana, Accra, Ghana, ⁵NYU Langone Hospital - Long Island, Mineola, NY, ⁶Lagos State University Teaching Hospital, Lagos, Nigeria, ⁷Lagos University State Teaching Hospital, Lagos, Nigeria, ⁸University of California San Francisco, Moss Beach, CA, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹Colton Center for Autoimmunity NYU School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more common and severe in those of African Ancestry (AA) who, relative to Europeans, are twice as likely to…
Abstract Number: 1270 • ACR Convergence 2021
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
Shirley Huang¹, Amy Guisinger², Carlyne Averell¹ and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), occurring in approximately 40% of SLE patients (pts) and often resulting in…
Abstract Number: 1505 • ACR Convergence 2021
Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
Latha Prabha Ganesan¹, Noushin Saljoughian¹, James Turman¹, Murugesan Rajaram¹, Brad Rovin², Wael Jarjour¹ and Samir Parikh², ¹Ohio State University, Columbus, OH, ²Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: We have recently identified inflammatory dendritic cells (InfDC) in human lupus kidneys. These cells are over expressed in LN patients compared to healthy controls.…
Abstract Number: 0353 • ACR Convergence 2021
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung⁵, Cherie Ng¹, Chandra Mohan⁶ and Chaim Putterman⁷, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU School of Medicine, New York, NY, ⁵Equillium, Inc., San Diego, CA, ⁶University of Houston, Houston, TX, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. While LN pathogenesis has yet to be…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1627 • ACR Convergence 2021
Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care
Dahima Cintrón¹, Suheiry Márquez¹ and Luis Vilá², ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Approximately 20% of patients with systemic lupus erythematosus (SLE) are diagnosed before 18 years of age. Pediatric patients have a worse disease course when…
Abstract Number: 0356 • ACR Convergence 2021
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
Lais Osmani, Sicong Shan, Zoe Chafouleas, Jason Pettus and Sladjana Skopelja-Gardner, Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Skin disease affects >80% of lupus patients and has been linked to lupus nephritis (LN) flares. We recently found that skin inflammation caused by…
Abstract Number: 1279 • ACR Convergence 2021
Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
Romina Nieto¹, Eduardo Ferreira Borba², Eugenia Settecasse³, Diana Fernandez-Avila⁴, Laura Maurelli⁵, Carla Gobbi⁶, Verónica Saurit⁷, Fernando Arizpe⁸, Julieta Daniele⁹, Maria Constanza Bertolaccini¹⁰, Eduardo Kerzberg¹¹, María de los Ángeles Gargiulo¹², Anabella Rodriguez¹³, Ana Carolina Londe¹⁴, Vitalina Sousa Barbosa¹⁵, Andrese Aline Gasparin¹⁶, Carolina Albanez A Cunha Andrade¹⁷, Luciana Parente Costa Seguro¹⁸, Lucas Victoria de Oliveira Martins¹⁹, Oscar Neira²⁰, Carolina Llanos²¹, Loreto Massardo²², Antonio Iglesias²³, Ivana Nieto Aristizábal²⁴, Gloria Vasquez²⁵, Paul Mendez-Patarroyo²⁶, Lizeth de la Hoz Rueda²³, José Martínez Pérez²⁷, Reyna Sánchez Briones²⁸, Mario Pérez Cristóbal²⁹, Eduardo Martin-Nares³⁰, Yaneli Juárez-Vicuña³¹, Yelitza Gonzalez Bello³², Jorge González García³³, Dionicio Galarza-Delgado³⁴, Marcos Vázquez³⁵, Patricia Langjarh³⁵, Magaly Alva Linares³⁶, Cristina Reategui-Sokolova³⁷, Armando Calvo Quirós³⁸, Edral Rodriguez³⁹, Ricardo Robaina⁴⁰, Martín Rebella⁴¹, Graciela Alarcn⁴², Ashley Orillion⁴³, Chetan Karyekar⁴⁴, Federico Zazzetti⁴⁵ and Guillermo Pons-Estel⁴⁶, ¹Hospital Provincial de Rosario, Rosario, Argentina, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Córdoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Córdoba, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ¹⁰Hospital Padilla, San Miguel de Tucumán, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, ¹⁵Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁷Universidad Federal de Pernambuco, Recife, Brazil, ¹⁸Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ¹⁹Universidad Federal São Paulo, São Paulo, Brazil, ²⁰Hospital del Salvador, Santiago, Chile, ²¹Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²²Universidad San Sebastián, Santiago, Chile, ²³Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁴Fundación Valle del Lili, Cali, Colombia, ²⁵Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, ²⁶Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, ³⁴Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Asunción, Paraguay, ³⁶Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁷Hospital Guillermo Almenara Irigoyen, Lima, Peru, ³⁸Hospital Cayetano Heredia, Lima, Peru, ³⁹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴⁰Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴¹Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴²University of Alabama at Birmingham, Birmingham, AL, ⁴³Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁴Janssen R&D, Spring House, PA, ⁴⁵Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁶Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life…